Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring
Cancers · 20.03.2026 · 18 (6) · 1014
DOI: 10.3390/cancers18061014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.03.2026. Verfasst von Kamil Safiejko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Cancer Unit, Maria Sklodowska-Curie Bialystok Oncology Center, 15-027 Bialystok, Poland. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Liquid biopsy using circulating tumor DNA (ctDNA) is rapidly reshaping gastrointestinal (GI) oncology. The highest-impact applications are molecular residual disease (mRD) detection after curative-intent therapy and early recognition of progression or resistance during systemic treatment.
Methods
We performed a structured, clinically oriented narrative synthesis by using explicit search, eligibility, evidence prioritization, and clinical interpretation rules, integrating landmark prospective cohorts, randomized ctDNA-guided strategy trials where available, meta-analyses, key methodological research (e.g., pre-analytics, assay design, and clonal hematopoiesis (CH)/clonal hematopoiesis of indeterminate potential (CHIP)), and selected trial registries.
Results
In resected colorectal cancer (CRC), postoperative ctDNA positivity is among the strongest known biomarkers of recurrence risk; large prospective studies demonstrate clear separation of disease-free survival (DFS)/overall survival (OS) between mRD+ and mRD− patients. In stage II colon cancer, randomized data (DYNAMIC) show that a ctDNA-guided strategy reduces adjuvant chemotherapy exposure without compromising long-term outcomes. In metastatic CRC, ctDNA supports early response monitoring and resistance tracking; ctDNA-selected anti-EGFR rechallenge provides a model of biomarker-driven actionability (CHRONOS). In gastroesophageal cancers, longitudinal ctDNA dynamics correlate with relapse risk and treatment efficacy, and in esophageal squamous cell carcinoma, ctDNA after neoadjuvant chemoradiotherapy informs residual disease risk and adjuvant stratification. In pancreatic ductal adenocarcinoma and hepatobiliary malignancies, sensitivity is constrained by low shedding and background cell-free DNA (cfDNA), yet ctDNA positivity remains clinically meaningful, and emerging data in resected extrahepatic cholangiocarcinoma (STAMP-linked analyses) show that ctDNA dynamics during adjuvant therapy predict recurrence. Conclusions: ctDNA is a clinically validated biomarker for mRD in CRC, whereas in other GI cancers, it remains a promising but methodologically heterogeneous tool whose clinical utility is tumor- and context-dependent. The next phase requires interventional trials demonstrating outcome improvement, harmonized sampling and reporting standards, and rigorous control of confounders (notably CH/CHIP).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Colorectal Cancer Unit, Maria Sklodowska-Curie Bialystok Oncology Center, 15-027 Bialystok, Poland.
- Institute of Biological Sciences, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
- Department of Pathology, Maria Sklodowska-Curie Bialystok Oncology Center, 15-027 Bialystok, Poland.
- Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
- Department of General Surgery, Faculty of Medicine, Bezmialem Vakif University, 34093 İstanbul, Türkiye.
- Institute of Medical Science, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
ORCID-Profile: Maciej Maslyk, Sebastian Radej, Lukasz Szarpak
Zitieren
APA
Safiejko, K., Juchimiuk, M., Pierko, J., Maslyk, M., Mucha, M., Koda, M., Konczuga-Koda, L., Radej, S., Akcakaya, A., & Szarpak, L. (2026). Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring. Cancers, 18(6), 1014. https://doi.org/10.3390/cancers18061014
Vancouver
Safiejko K, Juchimiuk M, Pierko J, Maslyk M, Mucha M, Koda M, et al. Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring. Cancers. 2026;18(6):1014. doi:10.3390/cancers18061014
BibTeX
@article{Safiejko2026,
author = {Safiejko, Kamil and Juchimiuk, Marcin and Pierko, Jacek and Maslyk, Maciej and Mucha, Mateusz and Koda, Mariusz and Konczuga-Koda, Luiza and Radej, Sebastian and Akcakaya, Adem and Szarpak, Lukasz},
title = {Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {1014},
doi = {10.3390/cancers18061014}
}
EUVIMED